{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:11:40Z","timestamp":1783102300496,"version":"3.54.6"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treating perihilar cholangiocarcinoma (PHCC) is particularly difficult due to the fact that it is usually in an advanced stage at the time of diagnosis. Irreversible electroporation treatment (IRE) involves the local administration of a high-voltage electric current to target lesions without causing damage to surrounding structures. This study investigated the safety and efficacy of using IRE in conjunction with intraoperative biliary stent placement in cases of unresectable PHCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study enrolled 17 patients with unresectable Bismuth type III\/IV PHCC who underwent IRE in conjunction with intraoperative biliary stent placement (laparotomic) in two medical centers in Asia between June 2015 and July 2018. Analysis focused on the perioperative clinical course, the efficacy of biliary decompression, and outcomes (survival).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean total serum bilirubin levels (mg\/dL) on postoperative day (POD) 7, POD30, and POD90 were significantly lower than before IRE (respectively 3.46 <jats:italic>vs<\/jats:italic> 4.54, p=0.007; 1.21 vs 4.54, p&amp;lt;0.001; 1.99 <jats:italic>vs<\/jats:italic> 4.54, p&amp;lt;0.001). Mean serum carbohydrate antigen 19-9 (CA19-9, U\/ml) levels were significantly higher on POD3 than before the operation (518.8 <jats:italic>vs<\/jats:italic> 372.4, p=0.001) and significantly lower on POD30 and POD90 (respectively 113.7 <jats:italic>vs<\/jats:italic> 372.4, p&amp;lt;0.001; 63.9 <jats:italic>vs<\/jats:italic> 372.4, p&amp;lt;0.001). No cases of Clavien-Dindo grade III\/IV adverse events or mortality occurred within 90 days post-op. The median progression-free survival was 21.5 months, and the median overall survival was 27.9 months. All individuals who survived for at least one year did so without the need to carry percutaneous biliary drainage (PTBD) tubes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>It appears that IRE treatment in conjunction with intraoperative biliary stent placement is a safe and effective approach to treating unresectable PHCC. The decompression of biliary obstruction without the need for PTBD tubes is also expected to improve the quality of life of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.710536","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T07:25:23Z","timestamp":1625037923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Po-Chih","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yang","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Bing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Zhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui-Quan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma \u2014 Evolving Concepts and Therapeutic Strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182708b57","article-title":"Evolution of Surgical Treatment for Perihilar Cholangiocarcinoma: A Single-Center 34-Year Review of 574 Consecutive Resections","volume":"258","author":"Nagino","year":"2013","journal-title":"Ann Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.211","article-title":"Classification of Biliary Tract Cancers Established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(Rd) English Edition","volume":"22","author":"Miyazaki","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003305","article-title":"A Study on Radial Margin Status in Resected Perihilar Cholangiocarcinoma","volume":"273","author":"Shinohara","year":"2019","journal-title":"Ann Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001441","article-title":"Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation: Safety and Efficacy","volume":"262","author":"Martin","year":"2015","journal-title":"Ann Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25110","article-title":"The Efficacy of Combination of Induction Chemotherapy and Irreversible Electroporation Ablation for Patients With Locally Advanced Pancreatic Adenocarcinoma","volume":"118","author":"Huang","year":"2018","journal-title":"J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.12.006","article-title":"Prognostic Factor Analysis of Irreversible Electroporation for Locally Advanced Pancreatic Cancer \u2013 A Multi-Institutional Clinical Study in Asia","volume":"46","author":"Yang","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2018.06.1806","article-title":"Safety and Efficacy of Irreversible Electroporation in the Treatment of Obstructive Jaundice in Advanced Hilar Cholangiocarcinoma","volume":"20","author":"Martin","year":"2018","journal-title":"HPB (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199201000-00005","article-title":"Management Strategies in Resection for Hilar Cholangiocarcinoma","volume":"215","author":"Bismuth","year":"1992","journal-title":"Ann Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6025-x","article-title":"8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers","volume":"25","author":"Chun","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000275","article-title":"Drainage-Related Complications in Percutaneous Transhepatic Biliary Drainage: An Analysis Over 10 Years","volume":"49","author":"Nennstiel","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2017161413","article-title":"Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series","volume":"284","author":"Sutter","year":"2017","journal-title":"Radiology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.08.011","article-title":"Recurrence After Curative-Intent Resection of Perihilar Cholangiocarcinoma: Analysis of a Large Cohort With a Close Postoperative Follow-Up Approach","volume":"163","author":"Komaya","year":"2018","journal-title":"Surgery"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10556","article-title":"Surgical Resection for Bismuth Type IV Perihilar Cholangiocarcinoma","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15050","article-title":"Combined Photodynamic Therapy With Systemic Chemotherapy for Unresectable Cholangiocarcinoma","volume":"49","author":"Gonzalez-Carmona","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i7.1278","article-title":"Success of Photodynamic Therapy in Palliating Patients With Nonresectable Cholangiocarcinoma: A Systematic Review and Meta-Analysis","volume":"23","author":"Moole","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-124870","article-title":"Efficacy and Safety of Endoscopic Radiofrequency Ablation for Unresectable Extrahepatic Cholangiocarcinoma: A Randomized Trial","volume":"50","author":"Yang","year":"2018","journal-title":"Endoscopy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3589","article-title":"Percutaneous Biliary Stenting Combined With Radiotherapy as a Treatment for Unresectable Hilar Cholangiocarcinoma","volume":"10","author":"Tan","year":"2015","journal-title":"Oncol Lett"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.710536\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T07:25:25Z","timestamp":1625037925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.710536\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":19,"alternative-id":["10.3389\/fonc.2021.710536"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.710536","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"article-number":"710536"}}